.25mg of semaglutide Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) approved exercise Wegovy (Semaglutide): Uses, Side Effects,

They will sterilize the insertion area, and then insert the IV needle

We can talk about gradually discontinuing treatment as your weight loss journey progresses

Semaglutide can attenuate inflammation in MASLD by downregulating the IRE1-XBP1-C/EBP (inositol-requiring transmembrane kinase/endonuclease-1-X-box binding protein 1-CCAAT/enhancer binding protein ) pathway in macrophages ( 2 ( 4.1.2 GLP-1RAs regulate the immune cells to protect the liver against fibrosis and neoplasia Exenatide and liraglutide can elevate cAMP levels and reduce the M1/M2 ratio through the cAMP-PKA-STAT3 pathway, resulting in amelioration of injured liver function and liver inflammation (Somm et al., 2021)

These drugs, derived from the hormone glucagon-like peptide-1, enhance insulin secretion, delay gastric emptying, reduce appetite, and promote weight loss [6]

This single decision shapes your entire dosing experience